Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Buy
61
RYTM Quote, Financials, Valuation and Earnings
Last price:
$117.57
Seasonality move
:
-9.01%
Day range:
$111.00 - $122.20
52-week range:
$45.91 - $116.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
42.93x
P/B ratio:
52.72x
Volume:
820K
Avg. volume:
826.4K
1-year change:
105.81%
Market cap:
$7.8B
Revenue:
$130.1M
EPS (TTM):
-$3.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$50.7M | -$0.73 | 32.11% | -3.96% | $127.00 |
|
ALT
Altimmune, Inc.
|
$560 | -$0.27 | -88.8% | -21.83% | $17.88 |
|
CDTX
Cidara Therapeutics, Inc.
|
-- | -$1.33 | -100% | -71.79% | $221.50 |
|
GILD
Gilead Sciences, Inc.
|
$7.5B | $2.14 | 1.21% | 32.99% | $131.65 |
|
TERN
Terns Pharmaceuticals, Inc.
|
-- | -$0.30 | -- | -28.56% | $51.11 |
|
VKTX
Viking Therapeutics, Inc.
|
-- | -$0.67 | -- | -182.02% | $93.39 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$117.57 | $127.00 | $7.8B | -- | $0.00 | 0% | 42.93x |
|
ALT
Altimmune, Inc.
|
$5.35 | $17.88 | $558.2M | -- | $0.00 | 0% | 21,246.46x |
|
CDTX
Cidara Therapeutics, Inc.
|
$220.19 | $221.50 | $6.9B | -- | $0.00 | 0% | 55.23x |
|
GILD
Gilead Sciences, Inc.
|
$123.21 | $131.65 | $152.9B | 19.08x | $0.79 | 2.55% | 5.33x |
|
TERN
Terns Pharmaceuticals, Inc.
|
$44.61 | $51.11 | $4B | -- | $0.00 | 0% | -- |
|
VKTX
Viking Therapeutics, Inc.
|
$37.53 | $93.39 | $4.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
63.6% | 0.747 | 3.86% | 4.31x |
|
ALT
Altimmune, Inc.
|
7.89% | 0.693 | 4.41% | 16.79x |
|
CDTX
Cidara Therapeutics, Inc.
|
0.47% | 3.325 | 0.07% | 4.47x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.042 | 18.1% | 1.16x |
|
TERN
Terns Pharmaceuticals, Inc.
|
0.36% | 0.860 | 0.16% | 19.21x |
|
VKTX
Viking Therapeutics, Inc.
|
0.11% | 1.448 | 0.03% | 27.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
$45.7M | -$52.7M | -65.1% | -509.34% | -102.64% | -$66.6M |
|
ALT
Altimmune, Inc.
|
-$22K | -$20.9M | -53.6% | -56.24% | -417180% | -$11.9M |
|
CDTX
Cidara Therapeutics, Inc.
|
-$28K | -$43.6M | -68.01% | -68.74% | -3675.83% | -$40.6M |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
TERN
Terns Pharmaceuticals, Inc.
|
-$111K | -$27.7M | -28.94% | -29.05% | -- | -$19.8M |
|
VKTX
Viking Therapeutics, Inc.
|
-$114K | -$98.6M | -28.59% | -28.62% | -- | -$94M |
Rhythm Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns RYTM or ALT?
Altimmune, Inc. has a net margin of -103.13% compared to Rhythm Pharmaceuticals, Inc.'s net margin of -380280%. Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34% beat Altimmune, Inc.'s return on equity of -56.24%.
Company Gross Margin Earnings Per Share Invested Capital RYTMRhythm Pharmaceuticals, Inc.89.08% -$0.82 $408.8M ALTAltimmune, Inc.-440% -$0.21 $201.5M -
What do Analysts Say About RYTM or ALT?
Rhythm Pharmaceuticals, Inc. has a consensus price target of $127.00, signalling upside risk potential of 21.22%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.88 which suggests that it could grow by 229.49%. Given that Altimmune, Inc. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Altimmune, Inc. is more attractive than Rhythm Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RYTMRhythm Pharmaceuticals, Inc.11 1 0 ALTAltimmune, Inc.5 1 1 -
Is RYTM or ALT More Risky?
Rhythm Pharmaceuticals, Inc. has a beta of 1.963, which suggesting that the stock is 96.257% more volatile than S&P 500. In comparison Altimmune, Inc. has a beta of -0.029, suggesting its less volatile than the S&P 500 by 102.89%.
-
Which is a Better Dividend Stock RYTM or ALT?
Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RYTM or ALT?
Rhythm Pharmaceuticals, Inc. quarterly revenues are $51.3M, which are larger than Altimmune, Inc. quarterly revenues of $5K. Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M is lower than Altimmune, Inc.'s net income of -$19M. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 42.93x versus 21,246.46x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RYTMRhythm Pharmaceuticals, Inc.42.93x -- $51.3M -$52.9M ALTAltimmune, Inc.21,246.46x -- $5K -$19M
-
Which has Higher Returns RYTM or CDTX?
Cidara Therapeutics, Inc. has a net margin of -103.13% compared to Rhythm Pharmaceuticals, Inc.'s net margin of -30201.66%. Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.
Company Gross Margin Earnings Per Share Invested Capital RYTMRhythm Pharmaceuticals, Inc.89.08% -$0.82 $408.8M CDTXCidara Therapeutics, Inc.81.53% -$3.10 $424.4M -
What do Analysts Say About RYTM or CDTX?
Rhythm Pharmaceuticals, Inc. has a consensus price target of $127.00, signalling upside risk potential of 21.22%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.6%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Cidara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RYTMRhythm Pharmaceuticals, Inc.11 1 0 CDTXCidara Therapeutics, Inc.1 6 0 -
Is RYTM or CDTX More Risky?
Rhythm Pharmaceuticals, Inc. has a beta of 1.963, which suggesting that the stock is 96.257% more volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.073%.
-
Which is a Better Dividend Stock RYTM or CDTX?
Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RYTM or CDTX?
Rhythm Pharmaceuticals, Inc. quarterly revenues are $51.3M, which are larger than Cidara Therapeutics, Inc. quarterly revenues of --. Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 42.93x versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RYTMRhythm Pharmaceuticals, Inc.42.93x -- $51.3M -$52.9M CDTXCidara Therapeutics, Inc.55.23x -- -- -$83.2M
-
Which has Higher Returns RYTM or GILD?
Gilead Sciences, Inc. has a net margin of -103.13% compared to Rhythm Pharmaceuticals, Inc.'s net margin of 39.21%. Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital RYTMRhythm Pharmaceuticals, Inc.89.08% -$0.82 $408.8M GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About RYTM or GILD?
Rhythm Pharmaceuticals, Inc. has a consensus price target of $127.00, signalling upside risk potential of 21.22%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $131.65 which suggests that it could grow by 6.85%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RYTMRhythm Pharmaceuticals, Inc.11 1 0 GILDGilead Sciences, Inc.16 8 0 -
Is RYTM or GILD More Risky?
Rhythm Pharmaceuticals, Inc. has a beta of 1.963, which suggesting that the stock is 96.257% more volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.
-
Which is a Better Dividend Stock RYTM or GILD?
Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.55% to investors and pays a quarterly dividend of $0.79 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios RYTM or GILD?
Rhythm Pharmaceuticals, Inc. quarterly revenues are $51.3M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 19.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 42.93x versus 5.33x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RYTMRhythm Pharmaceuticals, Inc.42.93x -- $51.3M -$52.9M GILDGilead Sciences, Inc.5.33x 19.08x $7.8B $3.1B
-
Which has Higher Returns RYTM or TERN?
Terns Pharmaceuticals, Inc. has a net margin of -103.13% compared to Rhythm Pharmaceuticals, Inc.'s net margin of --. Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34% beat Terns Pharmaceuticals, Inc.'s return on equity of -29.05%.
Company Gross Margin Earnings Per Share Invested Capital RYTMRhythm Pharmaceuticals, Inc.89.08% -$0.82 $408.8M TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M -
What do Analysts Say About RYTM or TERN?
Rhythm Pharmaceuticals, Inc. has a consensus price target of $127.00, signalling upside risk potential of 21.22%. On the other hand Terns Pharmaceuticals, Inc. has an analysts' consensus of $51.11 which suggests that it could grow by 14.57%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Terns Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RYTMRhythm Pharmaceuticals, Inc.11 1 0 TERNTerns Pharmaceuticals, Inc.8 0 0 -
Is RYTM or TERN More Risky?
Rhythm Pharmaceuticals, Inc. has a beta of 1.963, which suggesting that the stock is 96.257% more volatile than S&P 500. In comparison Terns Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RYTM or TERN?
Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Terns Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RYTM or TERN?
Rhythm Pharmaceuticals, Inc. quarterly revenues are $51.3M, which are larger than Terns Pharmaceuticals, Inc. quarterly revenues of --. Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M is lower than Terns Pharmaceuticals, Inc.'s net income of -$24.6M. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Terns Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 42.93x versus -- for Terns Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RYTMRhythm Pharmaceuticals, Inc.42.93x -- $51.3M -$52.9M TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M
-
Which has Higher Returns RYTM or VKTX?
Viking Therapeutics, Inc. has a net margin of -103.13% compared to Rhythm Pharmaceuticals, Inc.'s net margin of --. Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.
Company Gross Margin Earnings Per Share Invested Capital RYTMRhythm Pharmaceuticals, Inc.89.08% -$0.82 $408.8M VKTXViking Therapeutics, Inc.-- -$0.81 $713.8M -
What do Analysts Say About RYTM or VKTX?
Rhythm Pharmaceuticals, Inc. has a consensus price target of $127.00, signalling upside risk potential of 21.22%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 148.84%. Given that Viking Therapeutics, Inc. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Rhythm Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RYTMRhythm Pharmaceuticals, Inc.11 1 0 VKTXViking Therapeutics, Inc.12 1 0 -
Is RYTM or VKTX More Risky?
Rhythm Pharmaceuticals, Inc. has a beta of 1.963, which suggesting that the stock is 96.257% more volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.
-
Which is a Better Dividend Stock RYTM or VKTX?
Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RYTM or VKTX?
Rhythm Pharmaceuticals, Inc. quarterly revenues are $51.3M, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 42.93x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RYTMRhythm Pharmaceuticals, Inc.42.93x -- $51.3M -$52.9M VKTXViking Therapeutics, Inc.-- -- -- -$90.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
61
PLAB alert for Dec 12
Photronics, Inc. [PLAB] is up 6.18% over the past day.
Buy
77
DHIL alert for Dec 12
Diamond Hill Investment Group, Inc. [DHIL] is up 44.46% over the past day.
Buy
100
WRBY alert for Dec 12
Warby Parker, Inc. [WRBY] is up 2.23% over the past day.
